KIT and neoplasm: Although the small-molecule tyrosine kinase inhibitor, imatinib, has shown optimum clinical activity in c-kit-driven GIST patients, the effects are often limited because of intrinsic and acquired resistance resulting in tumour recurrence and progression in most patients (Schroeder et al. 2020).